A Chip Stock Gets Checked - Behind the Drop in Intel; and Gilead’s Remdesivir Gets the Green Light
Intel shares plunged after the company reported weak results for its data center group. What’s next for the stock that’s been far underperforming the rest of the semi sector. And Gilead gets FDA approval for remdesivir. We break down the rest of the race for a COVID vaccine.
Audio is streamed directly from the publisher (dts.podtrac.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
Intel shares plunged after the company reported weak results for its data center group. What’s next for the stock that’s been far underperforming the rest of the semi sector. And Gilead gets FDA approval for remdesivir. We break down the rest of the race for a COVID vaccine.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.